Hypertrophic Cardiomyopathy

Penulis

  • Ni Luh Putu Rustiari Dewi RS Universitas Udayana, Jimbaran, Bali, Indonesia

DOI:

https://doi.org/10.55175/cdk.v46i12.390

Kata Kunci:

Hypertrophic cardiomyopathy (HCM)

Abstrak

Hypertrophic cardiomyopathy (HCM) merupakan kelainan jantung primer yang diturunkan secara genetik dengan karakteristik penebalan
abnormal jaringan otot terutama ventrikel kiri tanpa kelainan jantung dan sistemik lainnya.Sekitar 60% kasus HCM diturunkan secara autosomal dominan berupa mutasi gen-gen protein sarkomer jantung. Diagnosis ditegakkan berdasarkan klinis, elektrokardiogram, ekokardiogram, atau cardiac magnetic resonance (CMR). Pemeriksaan genetik dapat dipertimbangkan. Terapi ß-blocker dan penyekat kanal kalsium digunakan untuk mengurangi gejala sulit bernapas, nyeri dada, penurunan aktivitas fisik, atau kelelahan. Intervensi invasif dengan ventricular septal myectomy (Morrow procedure) atau alcohol septal ablation. Evaluasi ulang secara berkala dan konseling genetik juga direkomendasikan termasuk pada pasien tanpa gejala.

Hypertrophic cardiomyopathy (HCM) is a primary cardiac disorder characterised by abnormal hypertrophy of cardiac muscle, usually of the left ventricle, in the absence of other cardiac or systemic conditions. Around 60% HCM patients have an autosomal dominant trait in cardiac sarcomere protein genes mutations. Diagnosis is established by clinical manifestation, electrocardiogram, echocardiogram, or cardiac magnetic resonance (CMR). Genetic test should be considered. Management consists of medications; ß-blocker and calcium channel-blocker are used to treat breathing difficulty, chest pain, decreased activity tolerance or fatigue. Invasive management are ventricular septal myectomy (Morrow procedure) or alcohol septal ablation. Periodic re-evaluation and genetic counseling is recommended, including in asymptomatic patients.

Unduhan

Data unduhan belum tersedia.

Referensi

Elliot PM. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Soc Cardiol. 2014;35:2733-79

Gersh BJ. Guideline for diagnosis and treatment of hypertrophic cardiomyopathy. AHA; 2011.

Marian Ali J, Braunwald E. Hypertrophic cardiomyopathy genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circulation. 2017;121:749-70.

Jacoby DL, DePasquale EC, McKenna WJ. Hypertrophic cardiomyopathy: Diagnosis risk stratification and treatment. CMAJ. 2013;185(2):127–34.

Afonso LC, Bernal J, Bax JJ, Abraham TP. Echocardiography in hypertrophic cardiomyopathy: The role of conventional and emerging technologies. Elsevier.2008;09:002.

Elliott P. Hypertrophic cardiomyopathy lifelong disease requiring lifelong treatment. Circulation. 2018;138:1399-401.

Rudski L. Hypertrophic cardiomyopathy and beyond – Echo Hawaii 2018. Jewish General Hospital [Internet]. 2018. Available from: https://www.asecho.org/wpcontent/uploads/2018/01/Rudski-Cardiomyopathies-Hypertrophic-Obstructive-Cardiomyopathy-and-Beyond.pdf

Nagueh S, Bierig SM, Budoff MJ, Desai M, Dilsizian V, Eidem B, et al. Guidelines and Standards American Society of Echocardiography Clinical Recommendations for multimodality cardiovascular computed tomography. J Am Soc Echocardiogr. 2011;24:473-98

Pandian NG, Rowin EJ, Gonzalez AM, Maron MS. Echocardiographic profiles in hypertrophic cardiomyopathy: imaging beyond the septum and systolic anterior motion. J Echo Res Pract. 2015;2(1):1-7.

Diterbitkan

2019-12-02

Cara Mengutip

Dewi, N. L. P. R. (2019). Hypertrophic Cardiomyopathy. Cermin Dunia Kedokteran, 46(12), 738–741. https://doi.org/10.55175/cdk.v46i12.390

Terbitan

Bagian

Articles